Filtered By:
Cancer: Bladder Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 355 results found since Jan 2013.
Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB
ConclusionOur study demonstrates that the PRR signatures are significantly associated with clinical-pathological features, the TIME, and prognostic features. The key PRR gene, P4HB, s a biomarker for the individualized treatment of BLCA patients.
Source: Frontiers in Immunology - September 18, 2023 Category: Allergy & Immunology Source Type: research
Autocrine motility factor receptor promotes the malignancy of glioblastoma by regulating cell migration and invasion
CONCLUSION: This study suggests that AMFR could be used as a therapeutic strategy for the clinical treatment of glioblastoma.PMID:37703903 | DOI:10.1080/01616412.2023.2257463
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Yao Zhang Xiuping Wang Guanghui Chen Yajing Lu Qiang Chen Source Type: research
GSE240039 Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS family protein ATAC
Contributors : Tomoyuki Nanamiya ; Kiyoko Takane ; Kiyoshi Yamaguchi ; Yoichi FurukawaSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensNectin-4 or PVRL4 is a promising therapeutic target because its augmented expression has been found in a wide range of human cancers. It is of note that Enfortumab Vedotin, an ADC for PVRL4 is clinically used for the treatment of urothelial bladder cancer. In addition, rMV-SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through an interaction with PVRL4. Although the transcripts of ...
Source: GEO: Gene Expression Omnibus - August 10, 2023 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies
Biomed Pharmacother. 2023 Jul 31;165:115242. doi: 10.1016/j.biopha.2023.115242. Online ahead of print.ABSTRACTBladder cancer (BC) is a common and serious type of cancer that ranks among the top ten most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the aggressive nature of cancer cells, and their resistance to medication, managing this disease has become a growing challenge in clinical care. Long noncoding RNAs (lncRNAs) are a group of RNA transcripts that do not code for proteins and are more than 200 nucleotides in length. They play a significant role in controlling cellular pathways and molecu...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 2, 2023 Category: Drugs & Pharmacology Authors: Amirreza Mehmandar-Oskuie Kasra Jahankhani Arman Rostamlou Sepideh Arabi Zahra Sadat Razavi Amirhossein Mardi Source Type: research
GSE236275 Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS family protein
Contributors : Tomoyuki Nanamiya ; Kiyoko Takane ; Kiyoshi Yamaguchi ; Yoichi FurukawaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNectin-4 or PVRL4 is a promising therapeutic target because its augmented expression has been found in a wide range of human cancers. It is of note that Enfortumab Vedotin, an ADC for PVRL4 is clinically used for the treatment of urothelial bladder cancer. In addition, rMV-SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through an interaction with PVRL4. Although the transcripts of PVRL4 are elev...
Source: GEO: Gene Expression Omnibus - July 31, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3
ConclusionUCA1 acted as an oncogene in pancreatic cancer by partly regulating miR-582-5p/BRCC3, which could be a new therapeutic target for pancreatic cancer.
Source: Frontiers in Oncology - July 25, 2023 Category: Cancer & Oncology Source Type: research
Exploring the correlation of glycolysis-related chondroitin polymerizing factor ( < em > CHPF < /em > ) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer
Am J Cancer Res. 2023 Jun 15;13(6):2213-2233. eCollection 2023.ABSTRACTBladder cancer (BLCA) is a common malignant neoplasm of the urinary system. Glycolysis is an essential metabolic pathway regulated by various genes with implications for tumor progression and immune escape. Scoring the glycolysis for each sample in the TCGA-BLCA dataset was done using the ssGSEA algorithm for quantification. The results showed that the score in BLCA tissues was markedly greater than those in adjacent tissues. Additionally, the score was found to be correlated with metastasis and high pathological stage. Functional enrichment analyses of...
Source: Cell Research - July 10, 2023 Category: Cytology Authors: Quliang Zhong Kehua Jiang Facai Zhang Yuan Tian Jiang Gu Tao Li Xulong Chen Jianjun Yang Fa Sun Source Type: research
Targeting Pro-Survival Autophagy Enhanced GSK-3 β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
Curr Oncol. 2023 May 28;30(6):5350-5365. doi: 10.3390/curroncol30060406.ABSTRACTAdvanced bladder cancer (BC) (local invasive and/or metastatic) is not curable even with cytotoxic chemotherapy, immune checkpoint inhibitors, and targeted treatment. Targeting GSK-3β is a promising novel approach in advanced BC. The induction of autophagy is a mechanism of secondary resistance to various anticancer treatments. Our objectives are to investigate the synergistic effects of GSK-3β in combination with autophagy inhibitors to evade GSK-3β drug resistance. Small molecule GSK-3β inhibitors and GSK-3β knockdown using siRNA promote...
Source: Current Oncology - June 27, 2023 Category: Cancer & Oncology Authors: Yuko Shirono Vladimir Bilim Tsutomu Anraku Hiroo Kuroki Akira Kazama Masaki Murata Kaede Hiruma Yoshihiko Tomita Source Type: research
